Korea Acute Myocardial Infarction Registry
The Korea Acute Myocardial Infarction Registry is a prospective, multicenter, observational registry designed to examine current epidemiology in hospital management and outcome of AMI in Korea for the commemoration of the 50 th anniversary of the Korean Circulation Society. The registry included 52 community and university hospitals for primary PCI with 1-year clinical follow-up. Data were collected at each site by a welltrained study coordinator based on a standardized protocol. 11- 13 Patients were enrolled in the registry after admission to participating hospitals with a suspected diagnosis of AMI. Patients' medical documents were used to collect demographic data, clinical characteristics and relevant laboratory and angiography results.
Subjects
A total of 1,839 consecutive metabolic syndrome patients with AMI (ST-segment elevation MI [STEMI] and non-STEMI [NSTEMI]) undergoing treatment for multivessel disease who were entered into the Korea AMI registry from November 2005 through December 2006, were assessed in this study. The prevalence of metabolic syndrome among the AMI patients was 47.1%. They were stratified into 2 groups based on the type of revascularization strategy: PCI with DES implantation (PCI-DES; n=1,715), and CABG (n=124). The primary endpoint was 12-month all-cause mortality. The choice of reperfusion adopted was at the operator's and/or patient's discretion.
Definitions and Clinical Endpoints
A final diagnosis of AMI was made according to the European Society of Cardiology/American College of Cardiology diagnostic criteria for AMI. 14 For the diagnosis of metabolic syndrome at baseline we followed the NCEP-ATP III criteria. Central obesity was defined as waist circumference >90 cm in men or >80 cm in women according to a modified ATP III guideline that World Health Organization-Western Pacific Region and International Association for the Study of Obesity presented for Asian populations in 2000. Metabolic syndrome was confirmed considering the presence of the following criteria: (1) central obesity (waist circumference >90 cm, men; >80 cm, women); (2) fasting triglycerides level ≥150 mg/dl; (3) reduced high-density lipoprotein cholesterol (<40 mg/dl, men; <50 mg/dl, women); (4) hypertension (blood pressure ≥130/85 mmHg or taking anti-hypertensive medication); and (5) impaired fasting glucose (fasting glucose ≥110 mg/dl, or taking medication or past history of type 2 diabetes mellitus). Patients were considered to have metabolic syndrome in the presence of ≥3 of the aforementioned criteria according to the definition proposed by American Heart Association/National Heart Lung and Blood Institute. Although that guideline recommended the definition of impaired fasting glucose ≥100 mg/dl, the present study adopted the NCEP-ATP III definition. 15 At the time of admission, history of hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg at rest, at repeated measurements, or treatment with anti-hypertensive medications. Diabetes mellitus was defined as use of oral hypoglycemic agent or insulin to lower blood glucose levels. Hyperlipidemia was defined as a total cholesterol level >200 mg/dl or treatment with a lipidlowering agent. Coronary artery disease was defined as history of MI, revascularization procedure, or obstructive coronary artery disease.
Peripheral blood samples were obtained using direct venipuncture. Blood samples were centrifuged and serum was removed and stored at a temperature of -70°C until the assay for sugar and proteins could be performed. Absolute creatine kinase (CK)-MB levels were determined by radioimmunoassay (Dade Behring, Miami, FL, USA). Cardiac specific troponin I levels were measured using paramagnetic particles in a chemiluminescent immunoenzymatic assay (Beckham, Coulter, Fullerton, CA, USA). Twelve-hour fasting serum levels of total cholesterol, triglyceride, and low-and high-density lipoprotein cholesterol were measured by standard enzymatic methods. Blood samples for high-sensitivity C-reactive protein (CRP) were obtained on admission and analyzed turbidimetrically with sheep antibodies against human CRP; this has been validated against the Dade Behring method.
2-D echocardiography was performed in all patients and left ventricular ejection fraction was assessed using modified Simpson's biplanar method. Presence of left main coronary artery stenosis was defined as a luminal stenosis ≥50%. Multivessel disease was defined as the presence of a lesion with >50% diameter stenosis in a non-infarct-related coronary artery. Successful PCI was defined as TIMI flow grade 3 with residual stenosis ≤50% in the infarct-related artery. In-hospital complications included any of atrioventricular block, bradycardia, ventricular tachycardia/ventricular fibrillation, atrial fibrillation, mitral regurgitation, cardiogenic shock, no re-flow, dissection, acute renal failure, metabolic acidosis/lactic acidosis, cerebrovascular event, respiratory impairment, mediastinitis or infection/sepsis.
Patients were treated with the intention of achieving complete revascularization of all vessels which were ≥1.5 mm in diameter with stenosis of ≥50%, as identified by local interventional cardiologist and cardiac surgeon. The choice of the specific type of DES was left to the operator's discretion. All patients were given loading doses of aspirin 325 mg and clopidogrel 300-600 mg before PCI regardless of DES type. Surgical revascularization was performed using a standard bypass technique; whenever possible, the internal thoracic artery was preferentially used for revascularization of left anterior descending artery. 16 Complete revascularization was performed with arterial conduits or saphenous vein grafts. Anticoagulation during PCI was performed with un-fractionated heparin according to the routine practice of each hospital. After the procedure, aspirin 100-200 mg (once per day) was prescribed indefinitely. Clopidogrel was prescribed continuously for 1 year.
The primary endpoint was 12-month all-cause death. We selected all-cause death because it is the most robust and unbiased index, because no adjudication is required, thus avoiding inaccurate or biased documentation and clinical assessment. 17 The secondary endpoint of the study was major adverse cardiovascular and cerebrovascular event (MACCE), defined as PCI-DES vs. CABG in MS Patients With AMI , or CABG) and cerebrovascular events. Nonfatal MI was defined as the presence of clinical symptoms, electrocardiographic change, or abnormal imaging findings of MI combined with an increase in CK-MB fraction or troponin T/I >99 th percentile of the upper normal limit that was not related to an interventional procedure. TVR was defined as clinically driven repeat revascularization of a lesion in the same epicardial vessel treated in the index procedure at 12-month follow-up. TLR was defined as any revascularization of the target lesion due to restenosis or re-occlusion <5 mm proximal/distal to the stent. Cerebrovascular events were defined as stroke, transient ischemic attack, and reversible ischemic neurological deficit as determined by a neurologist and confirmed on imaging. All data were recorded on a standardized, electronic, Web-based registry (http://www.kamir.or.kr).
Statistical Analysis SPSS 17.0 for windows (SPSS, Chicago, IL, USA) was used for all analysis. Continuous variables are given as mean ± SD; comparisons were done using Student's t-test. Discrete variables are given as percentages and frequencies; comparisons were done using chi-squared statistics or Fisher's exact test as appropriate. P<0.05 was considered statistically significant. Using Cox proportional hazard analysis, a model with independent predictive factors was constructed. Variables with P<0.05 or those that may be associated with AMI prognosis were selected for entry into the model. We performed propensity score adjustment to enable an even more rigorous adjustment 
Results
A total of 1,839 consecutive metabolic syndrome patients with AMI undergoing treatment for multivessel coronary artery disease were selected for this study. They were stratified into 2 groups based on the type of revascularization strategy: PCI-DES (n=1,715) or CABG (n=124 Baseline clinical, laboratory and angiographic characteristics, and concomitant medications of the 2 groups are presented in Table 1 . Patients in the CABG group were older with lower BMI and left ventricular ejection fraction, and higher heart rate and Killip class. They had a higher incidence of diabetes mellitus, hypertension, and previous coronary artery disease. Patients in the PCI-DES group had a higher prevalence of smoking and of STEMI.
According to laboratory findings, the CABG group had higher levels of serum glucose and NT pro-BNP, whereas CK-MB was higher in the PCI-DES group. Serum creatinine tended to be higher in the CABG group and troponin-I tended to be higher in the PCI-DES group. Other laboratory characteristics were not statistically different between the 2 groups. Coronary angiographic characteristics showed 3-vessel disease, left main coronary artery disease and left anterior descending artery disease to be higher in the CABG group, whereas 2-vessel disease was higher in the PCI-DES group.
There was no case reported of respiratory impairment after CABG, but the PCI-DES group had 2 cases (0.1%). Incidence of atrial fibrillation was higher in the CABG group compared to the PCI-DES group, although statistically not significant (1.6% vs. 1.3%, P=0.801). There was only 1 case (0.8%) of mediastinitis reported after CABG (P<0.001).
A total of 82 deaths (5.2%; 71 in the PCI-DES group and 11 in the CABG group) occurred in the 12-month follow-up period. Twelve-month clinical outcomes are presented in Table 2 . The incidence of the primary endpoint, 12-month all-cause mortality, was higher in the CABG group than in the PCI-DES group (12.2% vs. 4.8%, P=0.014). All-cause death was mainly attributable to cardiac death, which was found to be higher in the CABG group (12.2% vs. 4.3% in the PCI-DES group, P<0.001).
Kaplan-Meier survival curves (Figure 1) showed no significant association of 12-month MACCE between the 2 groups (log-rank P=0.448), but did show significant association of 12-month death between the 2 groups (log-rank P=0.007). Cox proportional hazard analysis (Figure 2 ) indicated significantly higher 12-month all-cause mortality in the CABG group when adjusted for age and gender (HR, 3.180; 95%CI: 1.219-8.299, P=0.018). When adjusted for multiple confounders, however, 12-month mortality was similar in the 2 groups (P=0.603). BMI ≥25 kg/m 2 , NT pro-BNP <3,000 pg/ml and heart rate >100 beats/min were the independent predictors of the primary endpoint in this study. Mortality at 12 months remained similar between the 2 groups despite propensity score adjustment using Cox model (P=0.485).
During follow-up, 98 patients (6.2%) had repeat PCI (PCI-DES, n=97; CABG, n=1), 10 patients (0.6%) had repeat CABG (PCI-DES, n=7; CABG, n=3) and 1 patient (0.06%) had undergone repeat PCI and CABG both. Repeat revascularization was significantly higher in the PCI-DES group (7.0% vs. 4.4% in the CABG group, P<0.001). Acute renal failure occurred in 18 patients: 15 (1.0%) in the PCI-DES group and 3 (3.3%) in the CABG group; and cerebrovascular events occurred in 14 patients: 10 (0.7%) in the PCI-DES group and 4 (4.4%) in the CABG group (P=0.001). There were no cases of stent thrombosis reported in the 12-month follow-up period.
The target group of the present study was patients with AMI (both STEMI and NSTEMI). It is said, however, that the outcome of STEMI is different to that of NSTEMI, which prompted us to conduct separate analyses on STEMI and NSTEMI alone. Kaplan-Meier analysis showed that patients with STEMI had similar survival probability between the 2 groups for 12-month MACCE (log-rank P=0.683) as well as 12-month death (log-rank P=0.377). After adjustment for multiple confounders using the Cox model, the risk of 12-month death was similar between the 2 groups (HR, 1.345; 95%CI: 0.117-15.439, P=0.812). The 12-month MACCE, however, differed significantly between the 2 groups (HR, 0.131; 95%CI: 0.019-0.889, P=0.038). Patients with NSTEMI had similar survival probability for 12-month MACCE between the 2 groups (log-rank P=0.782), but 12-month death differed significantly between the 2 groups (log-rank P=0.02). After adjustment for multiple confounders using Cox model, however, the risk of 12-month MACCE (HR, 1.705; 95%CI: 0.442-6.582,
Discussion
In the present study on metabolic syndrome patients with AMI, the adjusted 12-month mortality risk for PCI-DES was found to be similar to that for CABG for the treatment of multivessel coronary artery disease. Repeat revascularization rate, however, was considerably higher in the PCI-DES group compared to the CABG group. Twelve-month MACCE-free survival was found to be higher for STEMI patients in the CABG group, whereas patients with NSTEMI had a similar risk of 12-month MACCE and of death.
It has previously been reported that 31% of patients with AMI had diabetes mellitus and 35% had impaired glucose tolerance, suggesting that two-thirds of patients with AMI had insulin resistance. 18 Insulin resistance is associated with several cardiovascular risk factors, including upper-body obesity, postprandial hyperglycemia, dyslipidemia, hypertension, hyperinsulinemia, hypercoagulability, and dysfunction of endothelial cells. 19 The prognostic importance of metabolic syndrome, however, compared with that of the sum of its individual components (obesity, systemic hypertension, elevated fasting glucose, elevated triglyceride, and low high-density lipoprotein cholesterol), has repeatedly been challenged. 20,21 A meta-analysis of 87 studies by Mottillo et al showed that metabolic syndrome maintains its prognostic value for cardiovascular outcomes independent of type 2 diabetes mellitus. 6 Additionally, Gazzaruso et al showed that the prevalence of metabolic syndrome (59.8%) was significantly higher in those with coronary artery disease than in those without coronary artery disease. 22 The choice of CABG or PCI for the treatment of multivessel disease depends on several factors, particularly the location and number of vessels involved. PCI generally is preferred in patients with 2-vessel disease not involving the proximal left anterior descending artery, whereas CABG is usually the revascularization procedure of choice when a large amount of myocardium is at risk, as in unprotected left main coronary artery disease and diffuse 3-vessel disease, particularly in diabetic patients. 16 The development of DES, releasing anti-proliferative drugs into the vessel wall to inhibit neointimal hyperplasia, has revolutionized PCI, dramatically reducing the incidence of in-stent restenosis and TLR, leading to favorable clinical outcomes. 23- 25 The Arterial Revascularization Therapies Study-II (ARTS-II) study, which compared outcomes with sirolimuseluting stents and the surgical arm of the ARTS trial, showed that DES had 1-year outcomes similar to those of CABG. 26 Park et al demonstrated that for the treatment of multivessel disease, PCI-DES had equivalent long-term mortality to CABG and that subsequent revascularization after index treatment was more common in patients treated with DES. 1 In contrast, a recent report showed that in patients with multivessel disease, DES was associated with an increased 1-year mortality rate compared with CABG. 4 In the present study, however, we observed no significant differences in 12-month mortality in metabolic syndrome patients with multivessel disease.
A meta-analysis on multivessel disease by Benedetto et al summarized results from observational studies on 24,268 patients and found that PCI-DES continues to be associated with a significantly higher risk of overall major adverse cardiac and cerebrovascular events due to an excess of redo-revascularization compared with CABG repeat revascularization. 5 Serruys et al also reported that MACCE at 12 months were significantly higher in the PCI group, because of an increased rate PCI-DES vs. CABG in MS Patients With AMI of repeat revascularization. 27 The rates of death and of MI were similar between patients who underwent CABG and those who underwent PCI-DES, whereas the rate of stroke was increased in the CABG group. These findings of similar death rates, increased repeat revascularization in the PCI-DES group and increased cerebrovascular events in the CABG group compared to the PCI-DES group (4.4% vs. 0.7%) hold good even in the cohort of metabolic syndrome patients in the present study.
The higher rate of death in the CABG group on univariate analysis could be attributable to high rates of several known predictors of mortality: higher prevalence of uncontrolled diabetes (58% in CABG vs. 37% in PCI-DES), more extensive and severe coronary disease (triple vessel disease: 75% vs. 41%; and left main coronary artery disease: 10.5% vs. 1.9%), hypertension, higher incidence of previous coronary artery disease, decreased left ventricular ejection fraction and higher Killip class. CK-MB and troponin I were higher in the PCI-DES group compared to the CABG group, which indicates that the area of infarction was broader in the PCI-DES group. NT pro-BNP, however, was higher in the CABG group than in the PCI group. Chronic hyperglycemia can glycosylate proteins and damage kidneys, leading to microvascular damage and hypertension. 28 It may also exert direct toxic effects on the vasculature, potentiating the development of atherosclerosis. 19 This could have led to a higher rate of acute renal failure in the CABG group (3.3% vs. 1.0% in the PCI-DES group). The difference in mortality may also be explained partly by the differences in patient groups, interventional practice and ethnicity. Nonetheless, after statistical adjustment for confounders, death was similar in both groups.
Contrary to general supposition, in metabolic syndrome patients, mean triglyceride level was low in both groups (<150 mg/dl) in the present study. This could be as per the diagnostic criteria of metabolic syndrome itself; older age; chronic kidney disease; or possibly influenced by heparin injection. Recent studies have reported a low incidence of DES thrombosis under prolonged therapy with dual anti-platelets, which prevents thromboembolic events. 29 This may explain the zero rate of 12-month stent thrombosis recorded in the present study.
More than 50% of STEMI patients suffer multivessel coronary artery disease, which is known to be associated with worse prognosis. 30 We found that CABG is more favorable for metabolic syndrome patients with STEMI and multivessel coronary artery disease, whereas patients with NSTEMI had similar risk of MACCE and death. Most of the time, once the culprit artery is treated by PCI, the other stenosed coronary arteries are either treated by staged PCI or by conservative therapy. In specific situations, however, for example triple vessel disease with left main coronary artery stenosis, anatomy not suitable for PCI, diabetes with triple vessel disease, depressed left ventricular ejection fraction and so on, CABG should remain an important part of the treatment algorithm. 30 Gu et al also demonstrated that surgical management during the acute and sub-acute phases of STEMI is associated with excellent 30-day and 1-year survival. 31 We strongly recommend further long-term randomized controlled trials in metabolic syndrome to further investigate the present findings.
Study Limitations
The present study was limited due to its retrospective nature and moderate sample size. The choice of revascularization was at the discretion of the treating physician and/or patient. The 12-month follow-up duration may not be sufficient to reflect the true long-term effect of PCI-DES as compared to CABG.
The CABG group had 3-vessel disease and/or left main coronary artery disease predominantly, whereas the PCI group had 2-vessel disease and 3-vessel disease equally. This might have had an impact on the outcomes of the 2 groups. In addition, the statistical analysis may have been underpowered as a result of the wide gap in the number of patients between the 2 groups. We tried to reduce this selection bias by statistical adjustment with propensity score matching. Hence, we consider this study valuable.
Conclusions
The present study shows that metabolic syndrome patients with AMI undergoing PCI-DES have a similar 12-month risk of mortality to those undergoing CABG for the treatment of multivessel coronary artery disease. The rate of repeat revascularization was found to be higher in the PCI-DES group. Twelve-month MACCE-free survival was higher for STEMI patients in the CABG group, whereas patients with NSTEMI had a similar risk of 12-month MACCE and death. We suggest further long-term randomized evaluation to support the present findings in this high-risk patient subset.
